Daewoong Pharmaceutical is poised to turn itself into an undisputed global pharmaceutical leader in 2014
- A giant step forward based on Open R&D and Reverse Innovation strategy
- Relentless R&D investment to expand its reach into global market and secure foothold in foreign markets
- Renewed focus on customer value improvement and pleasant working environment
As the new year dawned, Daewoong Pharmaceutical Co.,Ltd(President: Lee Jong-wook) renewed its determination to take a giant leap forward to turn itself into a global pharmaceutical company in the new year kick-off meeting held at its head office in Samseong-dong on January 2, which was attended by all employees.
In this new year kick-off meeting, Lee Jong-wook, President of Daewoong Pharmaceutical, unveiled the vision statement that would shape the business management policy for 2014, presenting his goals to transform Daewoong Pharmaceutical into an undisputed global pharmaceutical leader, strengthen customer value, and create pleasant work environment. For that, Daewoong Pharmaceutical will cement its leadership in domestic pharmaceutical market, relentlessly push forward R&D and new drug development, and expand strategic base in global market to spur the export.
This year, Daewoong Pharmaceutical is on track to aggressively proceed with the export of its mainstay products, such as Urusa and NABOTA, etc., by fully leveraging its Reverse Innovation strategy and open R&D(Connect & Development) in a bid to thrust itself into a leading position in global pharmaceutical sector. Moreover, Daewoong Pharmaceutical plans to make the best use of global research network to focus on developing the incrementally modified drug that can gain ground in domestic and overseas markets. In addition, Lee Jong-wook, President of Daewoong Pharmaceutical, stressed the need to sharpen the manufacturing competitiveness with the production system conforming to CGMP (Current Good Manufacturing Practice).
Specifically, he put forth the vision to increase the customer value through the differentiated consulting business, achieve the corporate culture rooted in communication and trust to create pleasant working environment. Besides, he vowed to further develop the learning environment and human resource system to foster the talents ushering in brighter future.
Last year, Daewoong Pharmaceutical poured its energy into identifying the future growth engines based on bold R&D and global investment to turn the crisis into opportunity amid the government-led drug price reduction, and successfully made foray into global market with its NABOTA, the botulinum toxin formulation, along with the acquisition of China-based Liaoning Baifeng.
Lee Jong-wook, President of Daewoong Pharmaceutical, said, "Last year, we successfully laid the foundation of global pharmaceutical company with the concerted effort of all employees to constantly make strides even amid unfavorable external and internal conditions. Using the encouraging results of previous year as springboard, we will take a giant step forward to become a model in domestic and overseas pharmaceutical markets and bring our business to the next advanced level."
|
By 
